Key facts
- Notable investors include Sancus Ventures.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Deffai
- ·The full record, as it builds
Funding rounds
No funding rounds for Deffai are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Deffai
Developer of an AI-native regulatory orchestration platform designed for biotech and pharmaceutical companies to accelerate clinical trials and FDA approvals. The company offers AI-powered advisory, FDA feedback anticipation, full FDA support, and GTM integration, enabling clinical teams to streamline the path from pre-IND to commercial market entry.
- Sector
- Information Technology
- HQ
- Sacramento, CA, United States
- Founded
- 2025
- Employees
- 4
- Website
- deffai.com/
- Ownership
- Privately Held (backing)
Deffai doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Deffai shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Deffai in its N-PORT filings yet. We sweep new filings monthly.